Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives : Episode 10
Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
